Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 23:13:853012.
doi: 10.3389/fphar.2022.853012. eCollection 2022.

Application of Traditional Japanese Drug Jidabokuippo in a Modern Society

Hajime Nakae  1 , Yasuhito Irie  1 , Toshiharu Kitamura  1 , Manabu Okuyama  1
Affiliations
Review

Application of Traditional Japanese Drug Jidabokuippo in a Modern Society

Hajime Nakae et al. Front Pharmacol. .

Abstract

Background: Jidabokuippo (JDI) () has been used in Japan to alleviate contusion-induced swelling and pain since medieval times. Method: This review investigated the effects of JDI on various symptoms in patients with trauma or static blood[TM1]. The PubMed and Igaku Chuo Zasshi databases were searched until 24 December 2021. We summarize the benefits of applying JDI to inflammatory conditions, including bruises. Results: JDI has been used to resolve blood [TM1] stasis, regulate qi in trauma patients, and treat inflammatory swelling and pain caused by rheumatoid arthritis and cellulitis. As the adverse event rate associated with JDI is low (1.3%), JDI is considered a safe drug. Conclusion: JDI can be used to resolve blood[TM1] stasis in trauma patients without adverse events associated with nonsteroidal anti-inflammatory drugs.

Keywords: adverse event; inflammatory swelling; made-in-Japan; static blood; trauma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Three-dimensional high-performance liquid chromatography profile of jidabokuippo. Nuphar japonica DC. contains major ingredients: nupharidine, deoxynupharidine, nupharamine, and nupharin. Quercus acutissima Carruth. contains quercitrin, scopoline, fraxin, and tannic acid. Ligusticum officinale (Makino) Kitag. contains cnidilide, neocnidilide, ligustilide*, senkyunolide*, butylphthalide, butylidenephthalide, pregnenolone, vanillin, coniferyl ferulate, ferulic acid, and scopoletin. Neolitsea cassia (L.) Kosterm. contains cinnamaldehyde*, cinnamyl acetate, phenylpropyl acetate, cinnamic acid*, and salicylaldehyde. Syzygium aromaticum (L.) Merr. and L.M.Perry contains acetyleugenol, chavicol, caryophyllene, humulene, caryophylla, eugenocide, eugeniin, higenamine, rhamnetin, and kaempferol. Rheum palmatum L. contains sennoside A*–F, rhein*, aloe emodin*, emodin*, chrysophanol*, naphthalene, catechin*, epicatechin, and cinnamic acid*. Glycyrrhiza glabra L. contains glycyrrhizin*, glabric acid, liquiritin*, liquiritin apioside*, liquiritigenin*, isoliquiritin*, licoricidin, licoricone, licoflavone, formononetin*, glycerol, and glycycoumarin*.*Shown in Panel 1).
FIGURE 2
FIGURE 2
Hypothetical mechanisms of jidabokuippo for acute and chronic inflammation.
FIGURE 3
FIGURE 3
Tender point of jidabokuippo. When abdominal tenderness at the right side of the paraumbilical site was observed, JDI might have been effective.
See this image and copyright information in PMC

References

    1. Akiyama O., Harada Y., Akiyama I., Suzuki M., Shimizu Y., Kondo A. (2020). Therapeutic Effects of Jidabokuippo for Painful Swelling from Head Injury. J. Neurosurg. Kampo Med. 6, 12–17. (in Japanese).
    1. Amagaya S., Sugishita E., Ogihara Y., Ogawa S., Okada K., Aizawa T. (1984). Comparative Studies of the Stereoisomers of Glycyrrhetinic Acid on Anti-inflammatory Activities. J. Pharmacobiodyn. 7, 923–928. 10.1248/bpb1978.7.923 - DOI - PubMed
    1. Asada S. (1981). Futsugo Yakushitsu Hokan Kuketsu. Tokyo: Kyowa Kikaku Ltd. (in Japanese).
    1. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al. (2000). Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. VIGOR Study Group. N. Engl. J. Med. 343 (1520–8), 1520–1528. 2 p following 1528. 10.1056/NEJM200011233432103 - DOI - PubMed
    1. Dalton B. R., Lye-Maccannell T., Henderson E. A., Maccannell D. R., Louie T. J. (2009). Proton Pump Inhibitors Increase Significantly the Risk of Clostridium difficile Infection in a Low-Endemicity, Non-outbreak Hospital Setting. Aliment. Pharmacol. Ther. 29, 626–634. 10.1111/j.1365-2036.2008.03924.x - DOI - PubMed